Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
TriSalus Life Sciences Inc. (TLSIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/26/2026: TLSIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.47 | 52 Weeks Range 0.42 - 2.25 | Updated Date 06/10/2025 |
52 Weeks Range 0.42 - 2.25 | Updated Date 06/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -84.67% | Operating Margin (TTM) -79.95% |
Management Effectiveness
Return on Assets (TTM) -85.52% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 29370602 |
Shares Outstanding - | Shares Floating 29370602 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
TriSalus Life Sciences Inc.
Company Overview
History and Background
TriSalus Life Sciences Inc. is a pharmaceutical company focused on developing and commercializing novel drug delivery systems. While specific founding dates and detailed historical milestones are not readily available in public domains, the company's trajectory has been marked by its commitment to advancing cancer treatments through its proprietary technologies.
Core Business Areas
- Oncology Therapeutics and Drug Delivery: TriSalus Life Sciences focuses on developing innovative solutions for the treatment of cancer. Their core business revolves around their proprietary drug delivery platform, which aims to improve the efficacy and reduce the toxicity of existing and novel chemotherapeutic agents. This includes intratumoral delivery of therapies to precisely target cancer cells and minimize systemic exposure.
Leadership and Structure
Information on the specific leadership team and detailed organizational structure of TriSalus Life Sciences Inc. is not extensively published in publicly accessible databases. As a privately held company, its leadership and internal structure are typically managed by its executive team and board of directors.
Top Products and Market Share
Key Offerings
- TriNavu2122 Drug Delivery System: The TriNavu2122 Drug Delivery System is TriSalus Life Sciences' flagship technology. It is designed for the precise, targeted delivery of therapeutic agents, particularly cytotoxic drugs, directly into tumors. The system aims to enhance drug concentration at the tumor site while minimizing exposure to healthy tissues, potentially leading to improved treatment outcomes and reduced side effects. Competitors in the broader drug delivery space include companies developing targeted therapies, liposomal drug formulations, and other local delivery mechanisms. Specific market share data for this proprietary system is not publicly disclosed.
Market Dynamics
Industry Overview
The oncology therapeutics market is a dynamic and rapidly growing sector within the pharmaceutical industry. It is characterized by significant investment in research and development, a focus on personalized medicine, and an increasing demand for more effective and less toxic cancer treatments. Advancements in drug delivery technologies are a key area of innovation, aiming to overcome challenges associated with drug efficacy, bioavailability, and patient tolerability.
Positioning
TriSalus Life Sciences positions itself as an innovator in targeted drug delivery for oncology. Their competitive advantage lies in their proprietary TriNavu2122 system, which offers a novel approach to intratumoral drug administration. They aim to differentiate themselves by offering a platform that can potentially enhance the effectiveness of existing therapies and enable the development of new treatment paradigms for various cancers.
Total Addressable Market (TAM)
The Total Addressable Market for advanced drug delivery systems in oncology is substantial and growing. This market encompasses the global spending on cancer treatments, where improved drug delivery can lead to better outcomes and potentially a reduction in overall treatment costs due to fewer side effects and improved efficacy. TriSalus Life Sciences aims to capture a portion of this market by offering a differentiated technology that addresses unmet needs in cancer therapy. Specific TAM figures are not publicly available for this niche but are estimated to be in the billions of dollars globally.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery technology (TriNavu2122)
- Focus on a critical and growing medical area (oncology)
- Potential for improved treatment efficacy and reduced toxicity
- Innovative approach to intratumoral drug delivery
Weaknesses
- Limited public information on historical performance and financials
- As a developer, significant reliance on clinical trial success and regulatory approvals
- Need for substantial capital investment for R&D and commercialization
- Relatively new entrant in a highly competitive pharmaceutical landscape
Opportunities
- Growing demand for targeted cancer therapies
- Potential for partnerships with established pharmaceutical companies
- Expansion of the TriNavu2122 platform to other therapeutic areas beyond oncology
- Advancements in interventional oncology procedures
- Increasing focus on minimizing side effects of cancer treatments
Threats
- Intense competition from other drug delivery technologies and novel cancer therapies
- Challenges in clinical trial recruitment and success rates
- Regulatory hurdles and lengthy approval processes
- Potential for rapid obsolescence with new scientific discoveries
- Funding challenges for development and commercialization
Competitors and Market Share
Key Competitors
- Other companies developing targeted drug delivery systems for oncology (e.g., Delcath Systems, Inc. (DCTH), although their focus is different)
- Companies developing novel chemotherapies with improved delivery mechanisms
- Companies specializing in intratumoral injections and localized cancer treatments
Competitive Landscape
TriSalus Life Sciences operates in a highly competitive and rapidly evolving field. Their advantage lies in their specific TriNavu2122 technology for intratumoral delivery. However, they face competition from a broad range of companies developing novel oncology drugs and diverse drug delivery strategies. Success will depend on demonstrating superior clinical outcomes, safety profiles, and cost-effectiveness compared to existing and emerging treatments.
Growth Trajectory and Initiatives
Historical Growth: As a privately held entity, historical growth data in terms of revenue or market expansion is not publicly available. The company's growth is likely measured internally through milestones such as R&D progress, clinical trial advancements, and strategic partnerships.
Future Projections: Future growth projections for TriSalus Life Sciences Inc. are not publicly available. As a company in the development phase, its future success is contingent on the successful progression of its drug delivery platform through clinical trials and subsequent market adoption.
Recent Initiatives: Specific recent initiatives are not widely publicized. However, the company's ongoing focus is likely on advancing its TriNavu2122 technology through further research, development, and clinical validation. Potential initiatives could include forging new strategic alliances or seeking additional funding to support its pipeline.
Summary
TriSalus Life Sciences Inc. is a promising, albeit private, company focused on advancing cancer treatment through its innovative TriNavu2122 drug delivery system. Its strengths lie in its proprietary technology and its targeting of a critical medical need. However, as a private entity, its financial performance and detailed strategic operations are not publicly accessible, making a comprehensive assessment challenging. The company's future success hinges on successful clinical trials, regulatory approvals, and its ability to navigate a competitive landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Publicly available company information and industry analysis reports.
- General knowledge of the pharmaceutical and biotech industry.
Disclaimers:
This JSON output is based on publicly available information as of the knowledge cutoff date and may not reflect the most current developments. TriSalus Life Sciences Inc. is a privately held company, and therefore, specific financial data and operational details are not publicly disclosed. This analysis is for informational purposes only and should not be considered investment advice. Investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TriSalus Life Sciences Inc.
Exchange NASDAQ | Headquaters Westminster, CO, United States | ||
IPO Launch date 2023-08-11 | CEO, President & Director Ms. Mary T. Szela B.S.N., M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 110 | Website https://trisaluslifesci.com |
Full time employees 110 | Website https://trisaluslifesci.com | ||
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.